Amgen's migraine drug succeeds in late-stage trial
- S&P little changed as energy weighs but financials edge up
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- Fed's Yellen says 'makes sense' to gradually raise interest rates
- UPDATE: Fed Beige Book: Wages gain modestly in most areas amid tight job market
- Mallinckrodt (MNK) Announces FTC Settlement
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Reuters) - Amgen Inc (NASDAQ: AMGN) said on Wednesday its migraine treatment met the main goal of reducing monthly migraine days in patients with episodic migraine in a second late-stage study.
Patients receiving 70 milligram of the drug, erenumab, experienced reduction of 3.2 days from baseline in monthly migraine days, while those on 140 milligram experienced reduction of 3.7 days. Those in the placebo experienced a 1.8-day reduction, the company said.
At baseline, patients were experiencing an average of 8.3 migraine days per month, Amgen said.
Amgen, which is co-developing the treatment with Swiss drugmaker Novartis AG (NASDAQ: NOVN), said patients received the injectable drug once monthly for six months.
Erenumab is also being tested for episodic migraine prevention and chronic migraine prevention.
Worldwide, about 90 percent of people diagnosed with migraine have episodic migraine, which is characterized by up to 14 migraine days a month, the company said.
Amgen's shares, which closed at $147.23 in regular trading, were up marginally after market on Wednesday.
(Reporting by Divya Grover in Bengaluru)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novan (NOVN) Enters Licenses Agrement for SB204 with Sato Pharmaceutical in Japan
- U.S. justices weigh detainee lawsuit against Bush officials
- U.S. Judge okays sale by Hanjin Shipping Co of Total Terminals stake
Create E-mail Alert Related CategoriesFDA, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!